Benitec announced this week that it has agreed to collaborate with Chinese biopharmaceutical shop Biomics Biotechnologies on the development of an expressed RNAi-based treatment for chronic hepatitis B infection.
Benitec said the companies first intend to develop a "project plan for target identification and validation." Once a target has been selected, it will advance through preclinical and clinical testing.
The companies will share all intellectual property arising from the partnership and will jointly develop and commercialize the resulting HBV drug, Benitec said. Additional terms were not disclosed.